Biotricity ( (BTCY) ) has released its Q2 earnings. Here is a breakdown of the information Biotricity presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biotricity Inc. is a Nevada-based company specializing in remote monitoring technology for preventative healthcare, focusing on real-time data collection and analysis to aid medical professionals. In its latest earnings report, Biotricity highlighted a notable increase in revenue, reaching $3.27 million for the quarter ended September 30, 2024, a rise from $2.89 million in the same quarter of 2023. The company’s gross profit also improved to $2.46 million from $1.99 million year-over-year. Despite these gains, Biotricity reported a net loss of $1.56 million for the quarter, reflecting ongoing operational and research expenses. The company’s total liabilities decreased slightly to $34.17 million from $35.92 million at the end of March 2024. Looking ahead, Biotricity’s management remains focused on expanding its product offerings and increasing its market presence, with expectations of continued revenue growth and improved liquidity through strategic business development and capitalization efforts.